The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Relmada expects to initiate its Phase 3 program in the first half of 2026
Guidelines aim to establish state-regulated veterinary blood banks
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Subscribe To Our Newsletter & Stay Updated